Last updated: 11/07/2018 07:58:34
A single dose pharmacokinetics (PK) study of GSK2434735 in healthy male volunteers
Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An exploratory First Time in Human (FTIH) study investigating the pharmacokinetics (PK), immunogenicity, safety and tolerability of GSK2434735 administered as a single low dose in healthy male subjects
Trial description: An exploratory First Time in Human (FTIH) study investigating the pharmacokinetics, immunogenicity, safety and tolerability of GSK2434735 administered as a single low dose in healthy male subjects
Primary purpose:
Basic Science
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Profile of Pharmacokinetics
Timeframe: 42 days
Secondary outcomes:
Safety and tolerability of GSK2434735 as assessed by telemetry and change from baseline in 12-lead Electrocardiograms (ECG)
Timeframe: 42 days
Safety and tolerability of GSK2434735 as assessed by change from baseline in blood pressure and heart rate
Timeframe: 42 days
Safety and tolerability of GSK2434735 as assessed by number of participants with adverse events
Timeframe: 42 days
Change from baseline for Clinical laboratory assessments (hematology, chemistry and urinalysis
Timeframe: 42 days
Assessment of human anti-drug antibodies (ADA) in blood
Timeframe: 42 days
Interventions:
Enrollment:
5
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Claire Ashman, Isabelle Pouliquen,. An investigation of the pharmacokinetics of a novel bi-specific antibody in an exploratory FTIH study. American Association of Pharmaceutical Scientists - 2013 National Biotechnology Conference. 2013
Medical condition
Asthma
Product
GSK2434735
Collaborators
Not applicable
Study date(s)
February 2012 to May 2012
Type
Interventional
Phase
1
Participation criteria
Sex
Male
Age
18 - 65 years
Accepts healthy volunteers
Yes
- Healthy male volunteers between 18 and 65 years of age
- Negative for pre-existing antibodies to GSK2434735.
- Clinically significant abnormalities.
- Current or past history of significant cardiac, respiratory, metabolic, renal, hepatic, neurological or gastrointestinal conditions.
Inclusion and exclusion criteria
Inclusion criteria:
- Healthy male volunteers between 18 and 65 years of age
- Negative for pre-existing antibodies to GSK2434735.
- Body weight greater than and equal to 50 kg -BMI 19 – 29.9 kg/m2.
- Lifelong non-smokers or ex-smokers of greater than 6 months
Exclusion criteria:
- Clinically significant abnormalities.
- Current or past history of significant cardiac, respiratory, metabolic, renal, hepatic, neurological or gastrointestinal conditions.
- Current evidence or recent history of an infective illness. -Vaccination within 3 weeks of screening
- History of severe allergic reactions, angio-oedema, anaphylaxis or immunodeficiency
Trial location(s)
Location
GSK Investigational Site
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ
Status
Study Complete
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2012-23-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereResults for study 114594 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website